Quiver Bioscience and QurAlis Partner to Develop Precision Therapies for Fragile X Syndrome

Quiver Bioscience and QurAlis Corporation Announce Research Collaboration to Develop Novel Therapies for Fragile X Syndrome CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Quiver Bioscience ("Quiver") and QurAlis Corporation ("QurAlis") have established a research collaboration to advance a gene-targeted therapeutic approach for Fragile X syndrome (FXS). The partnership aims to leverage Quiver’s innovative "Genomic Positioning System" (GPS) drug discovery platform alongside QurAlis’ expertise in developing next-generation precision medicines for neurodegenerative and neurological conditions, with the ultimate goal of building a robust data package to support the development of a potentially transformative treatment for FXS. Quiver’s GPS platform combines scalable human neuronal electrophysiology data, which captures the 'language' of the brain, with artificial intelligence (AI) and machine learning (ML) to gain deep insights into disease biology and optimize drug discovery processes. Quiver has already applied this platform successfully to various central nervous system (CNS) disorders and recently published their findings on modeling and drug discovery efforts specifically for FXS. "Quiver’s platform technology is uniquely positioned to enhance our understanding of the molecular and cellular mechanisms underlying neurogenetic disorders like FXS," said Graham Dempsey, Ph.D., co-founder and CEO of Quiver Bioscience. "We are thrilled to partner with QurAlis, whose expertise aligns perfectly with our mission to bring groundbreaking therapies to the FXS community." FXS is a severe neurodevelopmental disorder and the leading inherited cause of intellectual disability and autism spectrum disorder. It affects approximately 87,000 individuals in the United States, occurring in about 1 in 4,000 males and 1 in 6,000 females. Common symptoms include developmental delays, seizures, speech difficulties, hyperactivity, attention deficit, and severe anxiety. Currently, there are no disease-modifying treatments available for FXS, creating a significant unmet medical need. Kasper Roet, Ph.D., CEO and co-founder of QurAlis, emphasized the importance of this collaboration. "FXS is a devastating condition that profoundly impacts the lives of those affected. As the leading cause of hereditary intellectual disability and a common cause of autism, the lack of effective treatments is deeply concerning. We are eager to collaborate with Quiver, combining our advanced technologies and drug development experience to progress novel therapeutics for FXS," he said. Destum Partners served as the transaction advisor to Quiver Bioscience, facilitating the partnership agreement. About Quiver Bioscience Quiver Bioscience is a technology-driven company focused on creating transformative medicines for brain-related disorders while uncovering new biological insights and identifying novel drug targets. Utilizing advanced single-cell imaging and multi-omics, Quiver is developing the world’s most comprehensive neuronal insight map through its "Genomic Positioning System." This integrated approach combines cutting-edge human models, proprietary engineering, and AI/ML to identify and optimize therapeutic candidates. For more information, including recent publications on the application of Quiver’s GPS in drug discovery, visit www.quiverbioscience.com or follow the company on LinkedIn. About QurAlis Corporation QurAlis is on a mission to cure neurodegenerative and neurological diseases by translating scientific breakthroughs into precision medicines. With a focus on collaboration and a relentless pursuit of knowledge, the company aims to develop medicines that can significantly improve the lives of patients. QurAlis leads in the development of precision therapies for amyotrophic lateral sclerosis (ALS) and is expanding its pipeline to address other severe, genetically defined diseases. For additional details, visit www.quralis.com or connect with QurAlis on X @QurAlisCo or LinkedIn.